A Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Maintenance IT-101 in Platinum Sensitive Ovarian Cancer Patients Who Received 4-6 cycles of a 2nd Line Platinum-Based Regimen Without Disease Progression
|Effective start/end date||9/30/08 → 4/23/09|
- Insert Therapeutics, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.